Corindus to Showcase CorPath® GRX Robotic System at EuroPCR 2019
20 Maggio 2019 - 12:45PM
Business Wire
Company will highlight CorPath GRX capabilities
in complex vascular procedures
Corindus Vascular Robotics, Inc. (“Corindus” or
the “Company”) (NYSE American: CVRS), a leading developer of
precision vascular robotics, announced today that it will showcase
advanced robotic capabilities of the CorPath GRX System at EuroPCR
2019 in Paris, France from May 21-24, 2019. Corindus will use the
annual meeting at EuroPCR 2019 to highlight recent milestones in
technology development, including the latest CE marked technIQ™
Smart Procedural Automation, automated movements aimed at improving
navigation, lesion crossing, and delivery of therapy.
The CorPath System is the world’s only U.S. Food and Drug
Administration (FDA) cleared and CE marked robotic platform for
percutaneous coronary intervention (PCI) and peripheral vascular
intervention (PVI) procedures. CorPath GRX received CE mark for
neurovascular intervention in April 2019, broadening the
application of the system to treat all vascular beds in the 33
countries that accept CE mark.
“As healthcare providers around the world continue to augment
their services with robotics, we are excited to showcase our latest
advancements of the CorPath GRX System at EuroPCR,” said Mark
Toland, President and Chief Executive Officer of Corindus. “We
truly value the opportunity to collaborate and engage with global,
influential industry leaders within the interventional community
and we’re honored to take part in EuroPCR for the first time.”
Jean Fajadet, M.D., Interventional Cardiologist at Clinique
Pasteur in Toulouse, France, PCR Vice-Chairman, and Course Director
of EuroPCR, oversaw the installation of CorPath GRX at Clinique
Pasteur earlier this year. The installation cemented the facility
as the first site in all of Europe to adopt the latest vascular
robotic technology.
“Partnering with Corindus has allowed us to lead the movement of
vascular robotics in Europe,” said Jean Fajadet, M.D.,
Interventional Cardiologist at Clinique Pasteur. “I am impressed
with the capabilities of CorPath GRX. The system’s ability to
control the guiding catheter, the guidewire, and the rapid exchange
catheter (balloon or stent) is critical to performing complex
procedures. Furthermore, our procedure rooms are equipped almost
entirely with remote capabilities. From imaging to procedural
control, our physicians have access to essentially everything they
need from the control room.”
EuroPCR, which is the annual meeting of the European Association
of Percutaneous Cardiovascular Interventions, will celebrate its
30th anniversary and will host more than 11,000 participants from
across the globe. For attendees interested in an exclusive
opportunity to gain firsthand experience with the latest smart
procedural automation technology available on the CorPath GRX
System, register here and visit Corindus at booth M49 through
Friday, May 24, 2019.
About Corindus Vascular Robotics, Inc.
Corindus Vascular Robotics is a global technology leader in
robotic-assisted vascular interventions. The Company’s CorPath®
platform is the first FDA-cleared medical device to bring robotic
precision to percutaneous coronary and vascular procedures. CorPath
GRX is the second generation robotic-assisted technology offering
enhancements to the platform by adding important key upgrades that
increase precision, improve workflow, and extend the capabilities
and range of procedures that can be performed robotically. We are
focused on developing innovative robotic solutions to revolutionize
treatment of emergent conditions by providing specialized and
timely medical care to patients around the world. For additional
information, visit www.corindus.com, and follow @CorindusInc.
Forward-Looking Statements
Statements made in this release that are not statements of
historical or current facts are "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements may involve known and unknown
risks, uncertainties and other factors that may cause the actual
results, performance or achievements of Corindus to be materially
different from historical results or from any future results or
projections expressed or implied by such forward-looking
statements. Accordingly, readers should not place undue reliance on
any forward-looking statements. In addition to statements that
explicitly describe such risks and uncertainties, readers are urged
to consider statements in the conditional or future tenses or that
includes terms such as "believes," "belief," "expects,"
"estimates," "intends," "anticipates" or "plans" to be uncertain
and forward-looking. Forward-looking statements may include
comments as to Corindus’ beliefs and expectations as to future
events and trends affecting its business and are necessarily
subject to uncertainties, many of which are outside Corindus’
control.
Examples of such statements include statements regarding or such
as:
- That Corindus will showcase advanced
robotic capabilities of the CorPath GRX System at EuroPCR 2019 in
Paris, France from May 21-24, 2019;
- Clinique Pastuer leads the movement of
vascular robotics in Europe; and
- The participants expected at the
European Association of Percutaneous Cardiovascular
Interventions.
Important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements
are described in the sections titled "Risk Factors" in the
Company's filings with the Securities and Exchange Commission,
including its most recent Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q, as well as reports on Form 8-K, including,
but not limited to the following: our ability to expand our
technology platform and achieve the advances necessary for
telestenting and remote procedures, including in humans; our
ability to expand our technology platform for use in other segments
of the vascular intervention market, including neurointerventional
and other more complex cardiac interventions; obtaining necessary
regulatory approvals for the use on humans and marketing of our
products in the United States and in other countries, including for
stroke and other neurovascular interventions; the rate of adoption
of our CorPath System and the rate of use of our cassettes; risks
associated with market acceptance, including pricing and
reimbursement; our ability to enforce our intellectual property
rights; our need for additional funds to support our operations;
our ability to manage expenses and cash flow; factors relating to
engineering, regulatory, manufacturing, sales and customer service
challenges; potential safety and regulatory issues that could slow
or suspend our sales; and the effect of credit, financial and
economic conditions on capital spending by our potential customers.
Forward looking statements speak only as of the date they are made.
Corindus undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise that occur after that date. More
information is available on Corindus' website at
http://www.corindus.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190520005107/en/
Corindus:Media Contact:Matter for CorindusJessica
WolterT: 978-518-4536corindus@matternow.comwww.matternow.com
Investor Contact:Lisa WilsonIn-Site Communications, Inc.T:
917-543-9932ir@corindus.com
Grafico Azioni Corindus Vascular Robotics (AMEX:CVRS)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Corindus Vascular Robotics (AMEX:CVRS)
Storico
Da Giu 2023 a Giu 2024